Drugs / QLS5132
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06932094 | May 2025 → May 2027 expected | cancer | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07453394 | Apr 2026 → Apr 2027 expected | endometrial cancer, gastric cancer, non-small cell lung carcinoma, ovarian cancer | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS5132 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07453394 ↗ |
| Modality | Other / unclassified | “antibody drug conjugate (ADC).” NCT06932094 ↗ |
| Route | Intravenous | “given IV every 3 weeks” NCT06932094 ↗ |